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Recent Advances in Mesoporous Silica Nanoparticles for 
Antitumor Therapy  
A. Baeza,
a,b
 M. Manzano,
a,b
 M. Colilla
a,b
 and M. Vallet-Regí
a,b,* 
Since 2001, when our research group proposed for the first time MCM-41 as drug release system, the scientific community 
is devoting growing interest to mesoporous silica nanoparticles (MSNs) for their revolutionary potential in nanomedicine. 
Among the diverse pathologies that can be treated with MSNs, cancer has received increasing attention. MSNs can be 
loaded with large amounts of therapeutic cargoes and once intravenously administrated  preferentially accumulate at solid 
tumours via enhanced permeation and retention (EPR) effect. Herein we report the recent developments achieved by our 
research group as a pioneer into this field, highlighting: the design of sophisticated MSNs as stimuli-responsive drug 
delivery systems to release the entrapped cargo upon exposure to a given stimulus while preventing the premature 
release of highly cytotoxic drugs before reaching the target; transporting non-toxic prodrugs and the enzyme responsible 
for its conversion into cytotoxic agents into the same MSN; improving the selectivity and cellular uptake by cancer cell by 
active targeting of MSNs; increasing the penetration of MSNs within the tumour mass, which is one of the major 
challenges in the use of NPs to treat solid tumours. 
1. Introduction 
Nanoparticles (NPs) capable to host, protect, transport and 
release therapeutic agents at target tissues, constitute one of 
the more exciting areas in modern nanomedicine.
1-4
 Among 
the different pathologies than can be treated with NPs, cancer 
has received outstanding attention.
5
 One of the main reasons 
relies on the fact that, once NPs are injected in the 
bloodstream, they preferentially accumulate in solid tumours 
due to the enhanced permeation and retention (EPR) effect. 
6, 
7
 This phenomenon involves that macromolecules greater than 
40 kDa or NPs intravenously administrated can leak out from 
the tumour blood vessels but not from healthy vessels. Normal 
vessels exhibit a well-organized branching hierarchy from large 
vessels into smaller vessels that feed a regularly spaced 
capillary bed. Contrarily, tumour blood vessels are abnormal, 
with wide interendothelial junctions, a high number of 
fenestrations, and transendothelial pores of several hundreds 
of nanometers.
8
 Therefore, when NPs are injected in the 
bloodstream they might extravasate through the fenestrations 
present in the tumour vessels and accumulate in the tumour 
interstitium. Besides, the extravasated NPs are retained within 
the tissue for long times because of an ineffective lymphatic 
drainage as a consequence of the fast growth of the tumour 
cells. On the contrary, conventional antitumor drugs are small 
and then they can pass through the vessels both in tumour and 
healthy tissues. Hence, they are rapidly eliminated from the 
bloodstream, and therefore high doses are needed to achieve 
therapeutic levels. Both, the need of high doses and the lack of 
selectivity of highly cytotoxic antitumor drugs usually provoke 
severe side effects in the patient that may compromise the 
efficacy of the therapy or even endanger the patient’s life.  
The encapsulation of antitumor drugs into NPs offers several 
advantages, including: i) their capability to improve the 
administration of hydrophobic drugs; ii) improving the 
pharmacokinetic release profiles; iii) capability to protect drugs 
against environmental aggressions (enzymatic degradation, pH 
variations, etc); iv) allowing high local concentrations; v) 
capability to transport more than one drug simultaneously; vi) 
capability to cross epithelial or endothelial barriers; vii) 
capability to monitor NPs trafficking and therapeutic efficacy 
using labelled NPs; and viii) selective accumulation into the 
tumour mass thanks to the EPR effect. It is worth of mention 
that the specific accumulation of NPs can be enhanced by 
grafting on their surface entities (antibodies, aptamers, or 
small molecules) capably of being selectively recognized by the 
surface of tumour cells. 
In recent years a great number of NPs have been reported for 
biomedical applications.
9-12
 Among them, mesoporous silica 
NPs (MSNs) are promising candidates owing their unique 
properties such as large surface areas (700-1000 m
2
 g
-1
) and 
large pore volumes (0.6-1 cm
3
 g
-1
), which provide high loading 
capacity, tuneable size (50-300 nm), shape and pore diameter 
(2-6 nm), robustness and easy functionalization.
13-26
 The 
features offer exceptional opportunities to host different 
therapeutic agents.
18, 27, 28
 On the other hand, MSNs can be 
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endocytosed by a huge number of mammalian cell lines, which 
depends on surface functionalization, size and morphology of 
NPs.
29-32
 In vitro toxicology of MSNs indicated that they were 
well-tolerated by different cell lines at dosages <100 µg mL
-1
,
33
 
and only transient metabolic alterations were produced.
34, 35
 In 
vivo biocompatibility of MSNs indicated that dosages <200 mg 
kg
-1
 were well-tolerated.
36
 The good he hemocompatibility, 
which is a requirement for intravenous administration, has 
been also demonstrated.
37, 38
  
Since 2001
13
 when our research group proposed for the first 
time MCM-41 mesoporous materials as drug release system, 
an impressive number of innovative advances into MSNs’ field 
have been reported worldwide. Herein we overview in a 
rational fashion the recent advances achieved by our research 
group as pioneer into the field of MSNs for nanomedicine.  
2. Stimuli-responsive drug delivery systems 
Drug release from conventional nanocarriers relays on the 
biodegradation of the nanoparticles in vivo, which makes very 
difficult to control the release of the drug. In this sense, 
stimuli-responsive drug delivery systems permit tailoring the 
release profiles with spatial, temporal and dosage control.
4, 25
  
MSNs can act as drug carriers thanks to the high specific 
surface area that present the mesoporous silica matrix. The 
diameter of the mesopores can be tuned in order to retain 
different therapeutic compounds from two to five 
nanometers, allowing the transportation of compounds of very 
different nature from small molecules to proteins, among 
others.
39
 However, if the transported compounds present high 
toxicity, as in the case of antitumor drugs, it is compulsory to 
design a strategy to avoid their premature release before 
reaching the target zone. As it has been mentioned above, 
MCM-41 type MSNs exhibit a unique pore network consisting 
in independent parallel pores without any connections 
between them. Thus, it is possible to obtain zero-release 
devices placing different moieties on the entrance of these 
pores which act as gate-keepers hampering the drug departure 
by steric hindrance or electrostatic repulsive forces.
40
 
Obviously, the attachment of these caps should be carried out 
in a reversible way for allowing the drug release once the 
nanodevice is in the diseased zone. This attachment should be 
performed through breakable bonds or employing moieties 
that might exhibit conformational changes which allow the 
drug departure.
41
 In our research group, several stimuli-
responsive MSNs have been designed in order to response to 
externally applied stimuli such as magnetic fields, light or 
ultrasounds which are described in detail below. 
 
Magnetic-responsive MSN 
The use of a magnetic field for triggering the drug release 
process presents interesting advantages for clinical 
applications due to its low toxicity and excellent penetration in 
living tissues. In order to exploit this stimulus a carrier able 
sensitive to the presence of magnetic fields should be 
designed. Thus, the most employed strategy consists in the 
encapsulation of superparamagnetic iron oxide nanocrystals 
(SPIONs) of 5–10 nm of diameter within the silica matrix. The 
exposition of SPIONs to alternating magnetic fields induces a 
significant temperature increase in the surroundings mainly 
due to two different mechanisms: Brownian relaxation, which 
implies the rapid rotation of the particles themselves and Neel 
relaxation, that is caused by the fluctuation of the magnetic 
moment within the particle.
42
 The efficient encapsulation of 
SPIONs within mesoporous silica matrices can be achieved 
using different strategies such as aerosol techniques
43
 or sol-
gel process,
44
 among others. Therefore, the presence of 
SPIONs inside MSNs allows the use of magnetic fields as trigger 
stimulus by placing thermosensitive moieties on the pore 
outlets which can be capable to suffer physic-chemical 
changes in response to temperature increases. The first 
temperature-responsive gatekeeper which was employed in 
our research group was DNA.
45
 When two complementary 
single DNA strands are in contact, they form a stable double 
helix structure thanks to the attractive intermolecular 
interactions between the base pairs adenine-thymine (AT) and 
guanine-cytosine (CT) in a process known as hybridization. This 
process is reversible and the two DNA strands can be 
separated at certain temperatures due to the rupture of these 
intermolecular forces producing the dehybridization of the 
double helix. The temperature at which this process takes 
place is called melting temperature, and it can be tuned by 
modifications in chain length, GC content, or controlling the 
density of oligonucleotides grafted on the particle surface.
46
 
Our magnetic-responsive device was based on MSNs which 
contained SPIONs trapped within the silica matrix (Magnetic 
Mesoporous Silica Nanoparticles, MMSNs). MMSNs were 
decorated in their external surface with 15 base pairs DNA 
single strands designed to exhibit a melting temperature of 
47
0
C that is located in the upper limit of hyperthermia range.
45
 
This device was capped with iron oxide nanoparticles 
decorated with the complementary DNA single strands 
through the hybridization between the two oligonucleotide 
chains (Fig. 1). This device can be loaded with drugs before the 
pore closure, displaying a zero-release performance at room 
temperature once the system is sealed. The application of an 
alternating magnetic field of 24 kA m
-1
 and 100 kHz induces a 
significant temperature increase in the particle surroundings 
up to reach the melting temperature, which produces the 
dehybridisation of the double helix and the subsequent drug 
departure. One interesting advantage of this system is its 
reversibility, because once the magnetic field is ceased, the 
DNA strands are self-assembled again leading to the pore 
closure. Thus, this device exhibit an on-off behaviour being 
capable of releasing the transported therapeutic agents in a 
more precise and controllable way. 
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Fig. 1. DNA-gated nanodevices (top) and thermosensitive-co-polymer coating 
(blue shell corresponds to PNIPAM and red chains correspond to PEI) (bottom).  
Thermosensitive polymers have been widely employed in 
nanomedicine both for the synthesis of temperature-
responsive organic nanoparticles,
47
 as well as for the creation 
of temperature-responsive gate-keepers placed on the surface 
of inorganic porous materials.
48
 Poly(N-isopropylacrylamide) 
(PNIPAM) has been one of the most employed systems among 
the temperature-responsive polymer family. When this 
polymer is dissolved in water it presents a linear state at 
temperatures below 32
0
C whereas it suffers shrinkage if the 
temperature exceeds this value. The temperature at which this 
transition takes place is known as lower critical solution 
temperature (LCST) and it can be tuned modifying the 
composition of the polymer chain. Thus, the co-polymerization 
of NIPAM with hydrophilic monomers such as acrylamide, 
acrylic acid or N-hydroxymethyl acrylamide (NHMA), among 
others, provokes an increase in their LCST due to the more 
favoured polymer-water interactions caused by the presence 
of these hydrophilic monomers.
49
 Therefore, through changes 
in the polymer composition it is possible to obtain PNIPAM co-
polymers in which the transition temperature is set around the 
hyperthermia range (42-45
0
C).
50
 In our research group, an 
engineered block co-polymer based on PNIPAM and 
polyethylene imine (PEI) has been grafted on the surface of 
MMSNs in order to provide two interesting properties: first, to 
act as temperature responsive gatekeeper able to control the 
release of drugs loaded within the pore network due to the 
presence of the PNIPAM backbone and, on the other hand, to 
retain proteins or enzymes within the polymer shell by 
electrostatic and hydrogen bond interactions between the 
housed macromolecules and PEI chains (Fig. 1). The presence 
of PEI increases the hydrophilic nature of the polymer chain 
rising the transition temperature up to ca. 40
0
C. Our device 
demonstrated its capacity to transport two species of different 
nature: fluorescein, as a small molecule model and Soybean 
Trypsin Inhibitor, similar to growth factors, as a protein 
example. The polymer shell collapses once the system is 
exposed to an alternating magnetic field producing the release 
of the loaded compounds. Recently, we have anchored on the 
MMSNs surface a random thermosensitive PNIPAM copolymer 
doped with 10% of NHMA in order to obtain a precise drug 
release triggered by magnetic fields when the temperature 
reaches 43
0
C.
51
 More importantly, this device was able to 
release the housed drugs under alternating magnetic 
exposition even keeping the local temperature at physiological 
conditions (37
0
C) placing the sample into a refrigerated 
chamber. This behavior proves that the presence of SPIONs 
within the silica matrix under magnetic field produces enough 
heat in the particle surroundings to induce the polymer 
collapse without the necessity to achieve a global temperature 
increment. This fact is of paramount importance for the future 
clinical application of magnetically triggered devices. 
 
Light-responsive MSN 
Light was one of the first stimuli employed for triggering the 
drug release in MSNs. Tanaka et al.
52
 grafted UV-light sensitive 
coumarin derivatives on the pore walls in order to control the 
drug departure process. The use of light presents several 
advantages as low toxicity, easy application and fine 
focalization in the target place. However, the main drawback is 
its poor tissue penetration. Despite this fact, a wide number of 
MSNs have been functionalized with light-sensitive moieties 
on their external surface in order to control the drug release 
by the exposition of light with different wavelengths, from UV 
to near infrared radiation.
53
 Our research group has recently 
reported the use of a responsive biocompatible protein shell 
able to act as light-cleavable gatekeeper which avoids the 
premature drug release. Additionally, the proteins attached on 
MSNs surface are capable to work as targeting agent 
enhancing the uptake by the tumour cells. This carrier is based 
on MSNs decorated with biotin molecules grafted on the 
surface through a light-sensitive cross-linker which suffer 
cleavage when is irradiated UV light at 366 nm (Fig. 2). Once 
the carrier is loaded with different cytotoxic compounds 
(doxorubicin or oxalilplatin), a solution of biotynilated 
transferrin and streptavidin seals the system thanks to the self-
recognition capacity of the biotin-streptavidin bridges. 
Transferrin is the protein in charge of iron transportation in 
human body. Many different tumour cell lines overexpress 
transferrin receptors in order to capture this valuable 
oligoelement.
54
 Therefore, the presence of transferrin on the 
external surface of these carriers not only act as sensitive cap 
of the housed drug but it also significantly enhances the 
particle uptake by the tumour cells up to ten times more than 
the naked particles. Once the carriers are internalized within 
the tumour cell, irradiation with UV light during a short period 
of time, less than 5 minutes, provokes the cleavage of the 
protein caps and then, the drug release. Surprisingly, these 
smart nanocarriers achieved a great cytotoxicity provoking 
that 100% of the cell population entered into apoptotic state 
using doses so low as 0.01 µg mL
-1
. The samples maintained in 
darkness conditions or the samples irradiated with UV light, 
but without particles, presented a same survival ratio than the 
controls. These results confirmed the capacity of these 
nanocarriers to destroy tumour cells in a controlled manner. 
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Fig. 2. Light-responsive protein shell in MSN which act as targeting agent and capping 
system at the same time. 
Ultrasound-responsive MSN 
Ultrasounds (US) represent an external stimulus that allows 
spatiotemporal control of the drug release at the desired site 
with very interesting features, such as: non-invasiveness, 
absence of ionizing radiations, cost effectiveness, and easy 
regulation of tissue penetration depth depending on 
frequency, cycles and exposure time. What is attractive of US 
in the field of nanomedicine is that high-frequency US can 
penetrate deep into the body with focused beams, which 
permits local therapies avoiding any damaging on healthy 
tissues.
55
  
Ultrasound waves propagate through living tissues provoking 
several physical effects that can be used as triggers for 
ultrasound-mediated drug release. In this sense, US inducing 
thermal and/or mechanical effects have been employed to 
trigger the release of drugs form different nanocarriers, such 
as liposomes and micelles.
55
  
The development of an US-triggered drug nanocarrier should 
be designed to respond to those physical effects generated by 
the US radiation. In this sense, mechanophores, chemical 
bonds that can be cleaved under US radiation,
56
 can be 
employed in the design of responsive NPs. This is the case of 2-
tetrahydropyranyl methacrylate (THPMA), a hydrophobic 
monomer with an acetal group sensitive to US, than can be 
easily be converted into hydrophilic methacrylic acid (MAA).
56, 
57
 This hydrophobic to hydrophilic phase transformation under 
US irradiation has been employed in the development of 
responsive MSNs using those moieties as gatekeepers of the 
pores.
58
 Additionally, those monomers were combined with 
thermoresponsive monomers, such as (2-(2-
methoxyethoxy)ethyl methacrylate, MEO2MA, to yield dual-
responsive copolymers, that is,  copolymers sensitive to US 
and heat. Grafting that copolymer on the surface of 
mesoporous silica nanoparticles allows: 
(1) loading the drugs into the already prepared NPs at low 
temperature (4
o
C), since the thermosensitive polymer 
presents an open conformation under these conditions. This is 
one of the great advantages of this system, because 
conventional MSNs load their cargo simultaneously to the 
functionalization process, which leads to low efficiency on 
loading and functionalization.  
(2) closing the pore entrances when temperature was 
raised to 37
o
C, since the thermosensitive polymer collapses at 
that temperature. This permits to the nanoparticles to carry 
the drugs avoiding any premature release, which is of 
tremendous importance when transporting cytotoxic drugs 
towards tumours, 
(3) releasing the drugs when irradiated with ultrasounds, 
since the US-sensitive polymer changes from hydrophobic to 
hydrophilic. This effect leads to a coil-like conformation of the 
copolymer, and, therefore, opens the gates of the pores 
allowing the release of their cargo. 
This ultrasound-responsiveness technology have been 
evaluated with different model molecules, fluorescein and the 
fluorescent ruthenium complex [Ru(bipy)3]
2+
, observing that 
nanocarriers respond efficiently to the stimulus independently 
of the nature of cargo transported.
58
 Additionally, these 
nanocarriers were observed to be non-cytotoxic and after 
internalisation into LNCaP cells, they retained their ultrasound 
responsive behaviour in the cytoplasm of those cells. When 
loading those MSNs with doxorrubicin and incubating with 
LNCaP cells, they induced cell death only once they were 
exposed to US, which means that the employed cytotoxic was 
only released after being triggered with the external stimulus, 
avoiding any type of premature release (no cell death) before 
US stimulation.
58
 
 
Fig. 3. Release profiles of fluorescein from MSNs functionalised with an US sensitive 
copolymer in PBS solution over time after 10 min of US irradiation (top) and without US 
(bottom). 
3. In situ cytotoxic drug generation. 
As it has been detailed above, the transportation of highly 
cytotoxic drugs, which is the common case of the nanocarriers 
with oncological application, demands the design of zero-
release devices, i.e., systems able to retain the cytotoxic 
species until reaching the target tissue or cell. This is the case 
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of the stimuli-responsive nanodevices mentioned in the 
previous section. The construction of these smart devices 
introduces in many cases high complexity that hampers their 
clinical application because the approval by regulatory 
agencies, which requires the extensive evaluation of all their 
components.
59
 Other alternative to address this issue consists 
in the development of systems able to transport the cytotoxic 
species in an inactive state and, once accumulated within the 
tumour area, activate them generating the toxic compounds 
only in the affected tissue. This strategy is exploited by the 
enzyme-prodrug approach which is usually based on the 
administration of harmless prodrugs which are activated by 
certain enzymes overexpressed by the tumour tissue.
60
 
Unfortunately, this strategy is limited in many cases by the low 
concentration of activating enzyme in the target tissue. 
Additionally, many prodrugs lack for a natural activating 
enzyme being necessary to co-administer them or to introduce 
the gene which encode them in the target cell.
61
 In our 
research group we have developed a nanocarrier able to 
generate highly toxic species within tumour cells transporting 
a non-toxic prodrug retained within the silica pore network 
and the enzyme required for its activation covalently attached 
on the particle surface.
62
 This system is composed by MSN 
functionalized with amino groups on the pore walls in order to 
retain by electrostatic interactions the prodrug, in this case 
indol-3-acetic acid (IAA). Horseradish peroxidase (HRP) 
transform IAA into indole-3-carbinol generating cytotoxic 
compounds in the process, mainly hydroxyl and reactive 
oxygen species (ROS), which are capable to destroy tumour 
cells by membrane and DNA damage.
63
 Enzymes are really 
labile materials which present low stability in living tissues due 
to the presence of proteases, among other aggressive agents. 
In our device, HRP were previously coated with a polymeric 
capsule designed to facilitate its grafting on MSNs surface 
whereas preserving its activity during longer times (Fig. 4). IAA 
is slowly released and activated by the HRP once the carrier is 
internalized within the tumour cells producing enough 
cytotoxic compounds to provoke the cell destruction. 
 
Fig. 4. In situ cytotoxic compound generation by prodrug-loaded MSN particles 
decorated with HRP nanocapsules.  
3. Selective targeting against tumour cells 
 
3.1. Active targeting 
Nanoparticles injected into the blood stream tend to be 
accumulated in tumour zones thanks to the particular blood 
vessel architecture of these diseased tissues.
64
 These vessels 
present high permeability as a consequence of the presence of 
large pores and fenestrations.
8
 Additionally, the fast growing 
rate of the tumour cells usually compress the lymphatic vessels 
compromising the drainage of the liquid, waste products and 
death cells in the tumour place. This fact enhances the 
accumulation of the nanoparticles in the zone which may 
remain there up to a few weeks. The combination of high 
permeability and enhanced retention is the basic of EPR effect 
being one of the most important asset of the use of 
nanoparticles in oncology, as was mentioned in the 
introduction section.
65
 However, tumour mass is not a 
homogeneous tissue composed only by tumour cells but it is a 
very complex tissue composed by many different cells.
66
 Thus, 
if an efficient destruction of the malignant cells is required, it is 
necessary to provide the nanocarrier the capacity to 
distinguish between the diseased cells and the myriad of 
different cells which form the neoplastic tissue. One of the 
most employed strategies to achieve this goal is the active 
targeting which consists in the decoration of the external 
surface of the nanoparticles with molecules or 
macromolecules able to interact with specific membrane cell 
receptors overexpressed by the tumour cells. This selective 
affinity between the nanocarrier and the tumour cell enhances 
the particle uptake.
67
 In our research group we have focused 
our attention initially in one particular type of cancer, 
neuroblastoma (NB). NB is the most frequent extracraneal 
cancer in pediatric oncology and it presents a poor prognosis 
despite the combination of several treatments as 
chemotherapy, radiotherapy, surgery and bone narrow 
transplant.
68
 More than 90% of NB cells overexpress a 
membrane protein in charge of the reuptake of 
norepinephrine, the norepinephrine transporter (NET).
69
 
Certain synthetic molecules as meta-iodobencylguanidine 
(MIBG) interact with this transporter in a similar way that the 
natural epinephrine.
70
 We have found that the attachment of a 
specific MIBG derivative, meta-aminobencylguanidine (MABG) 
through a cross-linker based on polyethylene glycol of 2000 Da 
of molecular weight (PEG2000) enhances the nanoparticle 
uptake by the NB cells in more than four times improving the 
cytotoxic capacity of the nanocarrier against this disease.
71
 
However, only the in vitro evaluation of the efficacy of a 
targeting agent is not enough to prove its suitability within 
complex living system. A targeting agent may be completely 
masked once the nanocarrier enters in contact with the 
proteins present in the blood stream, which commonly form a 
protein corona on the particle surface.
72
 Moreover, the fact 
that a certain targeting agents works well in in vitro conditions, 
even with particles suspended in multiprotein serum which 
mimic the blood composition, do not guarantee its suitability 
in a real situation, where the nanocarriers might be 
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accumulated in other organs such as liver, spleen, lungs, etc.
73
 
In order to conveniently evaluate our targeting device, we 
have employed a xenograft murine model in which the NB cells 
express luciferase which permits an easy visualization of the 
tumour mass by luminescence measurements. MSNs were 
labeled with a near infrared fluorophore (Cy7) for allowing the 
tissue localization of the NPs within the living organism. MSN 
functionalized with the targeting agent (group IV) showed a 
much higher accumulation within the tumour mass at 48 and 
72 hours after the administration in comparison with the 
particles functionalized simply with PEG2000 and the naked 
particles (Fig. 5).  In contrast, the PEGylated particles (group III) 
were mainly accumulated in the liver, probably due to the 
longer circulation time of these particles in contrast with the 
naked ones (group II) which were completely removed from 
the host. Moreover, the NPs functionalized with the MABG 
analogue remain in the tumour after 72 hours whereas the 
other ones are rapidly cleared from the zone. 
 
 
 
 
Figure 5. In vivo evaluation of the targeting efficacy of MSN decorated with the 
MABG derivative. 
 
3.2. Highly penetrative nanocarriers in 3D tumour models 
One of the most important problems of the use of 
nanocarriers to treat tumours is the poor penetration of the 
nanodevices within the tumour mass. As it was mentioned 
above, once the NPs reach the highly permeable tumour blood 
vessels, they pass through the pores presents in the vessel 
walls diffusing along the tissue. However, the diffusion rate of 
an object is ruled by the Stokes-Einstein equation which 
implies that the diffusion (D) is inversely proportional to the 
hydrodynamic radius (r) and the viscosity of the medium (η).
74
 
D = kT/6πηr 
 
NPs are big objects and therefore, their diffusion within the 
tumour is highly hampered. Moreover, the extracellular matrix 
of the tumour mass usually presents a high content of 
collagen, which makes it denser than the matrices present in 
healthy tissues. The higher density of the tumour tissues 
compromises even more the penetration of the nanocarrier. 
The administration in the tumour zone of proteolytic enzymes, 
as collagenase, able to digest the extracellular matrix prior to 
the NPs treatment enhances the penetration of the 
nanocarriers within the diseased zone and therefore, their 
therapeutic efficacy.
75
 These enzymes have also been directly 
attached by covalent bonds on the nanocarrier surface.
76
 
However, as mentioned above, enzymes are very sensitive 
molecules which may suffer denaturalization or degradation in 
a high range of conditions. Our research group has gone one 
step forward developing pH-sensitive collagen nanocapsules 
which were attached on MSN surface in order to improve the 
particle penetration in 3D tissues.
77
 In our device, collagen was 
coated by radical polymerization employing three different 
monomers: acrylamide (Am) as structural monomer, 2-
aminoethylmethacrylate (Am) which provides amino groups on 
the capsule surface necessary for the capsule attachment on 
MSN surface and ethylene glycol dimethacrylate (EG) as pH-
cleavable cross-linker which is the responsible for the rupture 
of the polymeric capsule and the subsequent collagenase 
release. Thus, MSNs transport these collagen nanocapsules 
attached on their surface (MSN-Col-nc) and, when the pH 
drops to mild acidic conditions that is typical for many 
different solid tumours as a consequence of the elevated 
glycolysis of the malignant cells,
78
 the capsules are broken 
releasing the collagenase which degrade the collagen matrix 
and enhances the penetration of the nanocarrier. The 
protective role of the polymer nanocapsules was tested 
exposing the system to a high concentration of proteolytic 
enzymes showing that the enzymatic activity of the 
transported collagenase remains intact. This higher 
penetration capacity of this novel nanodevice was tested using 
3D-collagen gel with Human Osteosarcoma cells embedded in 
order to provide a more realistic model which mimics a solid 
tumour. The results showed that MSN-Col-nc, labeled with 
fluorescein in order to achieve an easy visualization of the 
particles by confocal fluorescence microscopy, were capable to 
penetrate deeper within the tissue reaching zones which are 
not accessible for the naked particles (Fig. 6). Additionally, the 
complete system is completely biocompatible which pave the 
way for its future application in the clinical field. 
 
Fig. 6. Action mechanism of MSN-Col-nc. Blue arrows in the TEM micrograph 
correspond to collagenase nanocapsules attached on MSN surface. 
 
 
3.3. Cellular vehicles of nanoparticles 
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As it was mentioned in the previous section, to achieve a 
deeper penetration of the nanocarriers within the tumour 
mass constitutes a great challenge. In this sense, human 
mesenchymal stem cells (MSCs) with migratory properties 
towards tumours have been successfully used as carriers of 
NPs.
79, 80
 These cells are accumulated in the tumour tissues 
and once there, they can navigate within the diseased tissue 
reaching deeper areas. A particular type of these MSCs derived 
from the decidua of human placenta, DMSCs, are a very 
homogeneous population, very easy to obtain, and, more 
importantly, besides their migration properties towards 
tumours, they have been observed to inhibit the growth of 
primary tumours and the development of new tumours.
81
 
Those DMSCs have been employed as carriers of MSNs 
towards tumour cells for cancer therapies.
82
 Once potential 
toxicity of the MSNs over DMSCs was discarded, the effect of 
MSN surface chemistry over cellular uptake was evaluated, 
finding that positively charged MSNs were better internalised. 
The particles were located inside lysosomes just after 
internalisation, but after 3 days they escaped the lysosomes 
into the cytoplasm. The retention time of the MSNs into the 
cells was found to be 5 days or longer, time enough for the 
cells to migrate to tumours. The capacity of cells migration was 
evaluated both in vitro and in vivo, observing that DMSCs 
retained their homing capacity towards tumours when 
carrying MSNs. Additionally, DMSCs with MSNs loaded with 
doxorubicin were able to induce cell death in NMU cancer cells 
when co-cultured in vitro, which showed that this DMSCs 
represent a promising platform for cancer therapy as carriers 
of NPs loaded with anticancer drugs. 
 
 
Fig. 7. Schematic representation of DMSCs as carriers of MSNs towards tumour 
tissue (top); SEM, TEM and DLS of MSNs (bottom left hand corner); and DMSCs 
with fluorescein-labelled MSNs internalized into their cytoplasm (bottom right 
hand corner). 
 
 
 
 
4. Futures Prospects 
In the last years, MSNs have become a powerful material in 
the war against cancer thanks to their interesting properties as 
high loading capacity, easy functionalization, robustness and 
low toxicity, among others. Many scientist along the world has 
extensively studied the use of this system generating smart 
stimuli-responsive materials and designing novel targeting 
strategies in order to improve its capacity to destroy tumour 
cells in a more controllable and accurate way. There are still 
different issues that are necessary to address in order to reach 
the real clinical applications, i.e., it is necessary to study the 
long-term toxicity of these devices or in the case of the stimuli-
responsive MSN, we should test their efficacy in more realistic 
conditions employing in vivo models or at least using in vitro 
models which mimics more properly the complexity of a living 
organism such as tumour spheroids, ex ovo chick embryo 
models or 3D cell co-cultures. In any case, the knowledge 
acquired during these years and the excellent results 
harvested until now are hopeful enough to think that in the 
coming years these smart nanocarriers will provide more 
efficient weapons to fight against this terrible disease. 
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